Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E

Biglia, Nicoletta; Sgandurra, Paola; Peano, Elisa; Marenco, Davide; Moggio, Giulia; Bounous, Valentina Elisabetta; Cont, Nicoletta Tomasi; Ponzone, Riccardo; Sismondi, P

doi:10.1080/13697130902736921

Cited by 50 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five randomized controlled trials compared a non-pharmacologic with a pharmacologic hot flash treatment in women with breast cancer (Table 1; Supplementary material 2) [25, 37–40]. These trials took place in Egypt, Italy, and the United States and were single-center studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

Johns

Seav

Dominick

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Patient-centered decision making about hot flash treatments often incorporates a balance of efficacy and side effects in addition to patient preference. This systematic review examines randomized controlled trials (RCTs) comparing at least two non-hormonal hot flash treatments in breast cancer survivors. In July 2015, PubMed, SCOPUS, CINAHL, Cochrane, and Web of Science databases were searched for RCTs comparing active, non-hormonal hot flash treatments in female breast cancer survivors. Thirteen trials were included after identifying 906 potential studies. Four trials were dose comparison studies of pharmacologic treatments citalopram, venlafaxine, gabapentin, and paroxetine. Hot flash reduction did not differ by tamoxifen or aromatase inhibitor use. Citalopram 10, 20, and 30 mg daily had comparable outcomes. Venlafaxine 75 mg daily improved hot flashes without additional side effects from higher dosing. Gabapentin 900 mg daily improved hot flashes more than 300 mg. Paroxetine 10 mg daily had fewer side effects than 20 mg. Among four trials comparing different pharmacologic treatments, venlafaxine alleviated hot flash symptoms faster than clonidine; participants preferred venlafaxine over gabapentin. Five trials compared pharmacologic to non-pharmacologic treatments. Acupuncture had similar efficacy to venlafaxine and gabapentin but may have longer durability after completing treatment and fewer side effects. We could not perform a pooled meta-analysis because outcomes were not reported in comparable formats. Clinical trial data on non-hormonal hot flash treatments provide comparisons of hot flash efficacy and other patient important outcomes to guide clinical management. Clinicians can use the information to help patients select hot flash interventions.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Acupuncture was compared with gabapentin or venlafaxine in two trials [25, 40]. Gabapentin was compared with vitamin E or hypnosis in two trials [37, 38]. Pregabalin was compared with stellate ganglion block in one study [39].…”

Section: Resultsmentioning

confidence: 99%

Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

Johns

Seav

Dominick

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…45 Similarly, studies of vitamin E for HF have not yielded encouraging results. 5,46 Although high vitamin use has been reported in previous studies of cancer population, some authors have suggested possible harm from the use of antioxidants while others indicated that patients derive benefits from such use. 47 The results of this study could be indicative of more women with hot flashes consuming vitamins in expectation of a relief; however, future research should ascertain the potential effects of vitamins on HF.…”

Section: Discussionmentioning

confidence: 99%

“…5 Hormonal treatment is effective in controlling HF; however, hormone replacement therapy is contraindicated in women with breast cancer. 6 Several non-pharmacologic treatments including Complementary and Alternative Medicine (CAM) modalities are commonly used by cancer patients; however, their efficacy is uncertain.…”

Section: Introductionmentioning

confidence: 99%

Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer

Chandwani

Heckler

Mohile

et al. 2014

EXPLORE

View full text Add to dashboard Cite

Context Hot flashes (HF) are a common distressing symptom in women with breast cancer (BC). Current pharmacologic options are moderately effective and are associated with bothersome side effects. Complementary and alternative medicine is commonly used by cancer patients. However, information on the association of hot flashes severity with such use and self-rated health is lacking. Objective To examine the hot flashes severity in women with breast cancer and its association with complementary and alternative medicine use and self-rated health (SRH). Design Longitudinal multicenter study to assess information needs of cancer outpatients. Participants Patients with a diagnosis of breast cancer who were scheduled to undergo chemotherapy and/or radiotherapy. Outcome Measures Hot flashes severity (0 = not present and 10 = as bad as you can imagine), use of complementary and alternative medicine (yes/no), and self-rating of health (SRH) status post-treatment and six-months thereafter (1–5, higher score = better SRH). Results The majority of women with HF (mean age = 54.4 years) were Caucasian and married, with higher education, and 93% had received surgical treatment for BC. At the end of treatment, 79% women reported experiencing HF [mean severity = 5.87, standard deviation (SD) = 2.9]; significantly more severe HF were reported by younger women with poor SRH, better performance status, and those reporting doing spiritual practices. At follow-up, 73% had HF (mean severity = 4.86, SD = 3.0), and more severe HF were reported by younger women with poor self-rated health who had undergone chemotherapy plus radiotherapy, used vitamins, and did not exercise. Conclusions A high percentage of women experienced hot flashes at the end of treatment and at six-month follow-up. A significant association of hot flashes severity with spiritual practice, increased vitamin use, and reduced exercise emphasize the need for future studies to confirm the results. This can facilitate safe use of complementary and alternative medicine and favorable outcomes while managing cancer-related hot flashes.

show abstract

“…Enfi n, dans une dernière étude comparant la gabapentine à la vit E (800 UI/j) comme traitement du groupe témoin, un effet très marginal de la vit E sur les bouffées de chaleur est noté avec une fréquence et un score réduit de 10 et de 7 % respectivement [13].…”

Section: Effets De La Vit E Sur Les Bouffées De Chaleur Chez Les Femmunclassified

Nutrition

Schneider¹,

Bachmann²,

Latino‐Martel³

et al. 2011

Oncologie

View full text Add to dashboard Cite

Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E

Abstract: Gabapentin appears to be effective for the treatment of hot flushes with a favorable effect on quality of sleep. Vitamin E has only marginal effect on vasomotor symptoms.

Cited by 50 publications

References 13 publications

Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer

Nutrition

Contact Info

Product

Resources

About